Holding(s) in Company

RNS Number : 2308M

Physiomics PLC

26 January 2009

 



Physiomics plc

The Magdalen Centre

The Oxford Science Park
Robert Robinson Avenue
Oxford

OX4 4GA
UK

Tel [phone]

Fax [phone]

26 January 2009            

Physiomics plc ('Physiomics' or 'the Company')

Holding in Company

The Company has been informed that following a sale of 4,000,000 Ordinary Shares of 0.04p each ('Ordinary Shares') on 21 January 2009 by Billam AG, and a subsequent sale on 22 January 2009 of 1,350,000 Ordinary Shares, Billam AG now holds 29,150,000 Ordinary Shares in the Company, representing 4.7% of the Company's total voting rights.

For further information:

Physiomics plc                                                    [phone]

Dr Christophe Chassagnole, COO 

E-mail: [e-mail]

Grant Thornton UK LLP                                       [phone]

Philip Secrett, Colin Aaronson

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates¹ show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

END

 

 

HOLBQLFLKFBXBBZ